Compare DexCom, Inc. (DXCM) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nokia Corp — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays a 1.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nokia Corp for 66 Days on average.
| DXCM | NOK | |
|---|---|---|
Market Cap | $31.86B | $56.99B |
Volume | 3,607,070 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $92.34 | $16.83 |
52-Week Low | $54.84 | $5.18 |
Typical Hold Time | 62 Days | 66 Days |
Enterprise Value | $31.32B | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Nokia (NOK) trades at $10.36, down 2.45% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, with a beat in Q2 2026 but a miss in Q1 2026. Revenue for 2025 was $19.89 billion, with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation disconnect, with a high P/E of 75.09 but strong analyst optimism—61.5% recommend Buy, with a consensus price target of $17.50. Upside catalysts include AI infrastructure demand and strategic partnerships, while risks involve competitive pressures and volatile cash flows, evidenced by a net cash outflow of $1.16 billion in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
